Aluminium sulfate 20% spray
Aluminum (Al), also spelled aluminum, chemical element, a lightweight, silvery-white metal of main Group 13 (IIIa, or boron group) of the periodic table [L2148].
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Aluminium sulfate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aluminium sulfate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 3 · 1960–2026
Showing the 50 most relevant studies, sorted by most relevant.
Doyon-Plourde P, Chong J, Abrams EM, et al.
2026
- Aluminum
- Vaccines
- Adjuvants, Immunologic
ObjectiveTo systematically review and critically appraise human evidence on potential health effects of aluminium adjuvanted vaccines.DesignSystematic review following PRISMA (preferred reporting items for systematic review and meta-analysis) 2020 guidelines.Data sourcesSix databases and trial registries were searched from inception to 3 March 2023 then updated to 27 November 2025. Reference lists of eligible studies were also screened.Eligibility criteria for selecting studiesHuman studies assessing health outcomes after aluminium adjuvanted vaccination, including randomised controlled trials, cohort studies, case series, and ecological studies. Investigational vaccines, case reports, and review articles were excluded.Data extraction and synthesisTwo reviewers screened studies (with AI assistance for the 2023-25 update), extracted data, and assessed risk of bias (using RoB 2.0, ROBINS-I, or an adapted tool for case series). Certainty of evidence was rated using GRADE (Grading of Recommendations Assessment, Development, and Evaluation).ResultsThe review included 59 studies (37 case series, 11 randomised controlled trials, nine cohort studies, two ecological studies). High quality evidence from randomised controlled trials and large cohorts consistently showed no association between aluminium adjuvanted vaccines and serious or long term health outcomes, such as asthma, autism spectrum disorders, or other chronic conditions. Studies on macrophagic myofasciitis were generally small and methodologically limited, and did not provide credible evidence of a causal association (very low certainty). Localised persistent nodules or granulomas were observed infrequently after diphtheria-tetanus-pertussis vaccines, consistent with delayed type hypersensitivity (ConclusionsCurrent evidence does not support causal associations between aluminium adjuvanted vaccines and serious or long term health outcomes. The most consistently documented reactions were persistent nodules or granulomas that are uncommon, local, and self-limited hypersensitivity reactions. These findings are broadly consistent with post-licensure surveillance findings. The predominance of methodologically limited studies for some outcomes highlights the need for higher quality research.Systematic review registrationPROSPERO CRD42023462831.
Abstract licence: CC BY-NC
Rim Ragoug, O. Metalssi, F. Barberon, et al.
Cement and Concrete Research, 2019
M. Soudagar, N. Nik-Ghazali, M. Kalam, et al.
Renewable Energy, 2020
N. Mobasher, S. A. Bernal, J. Provis
Journal of Nuclear Materials, 2016
P. V. Nidheesh, Jayraj Khatri, Jayraj Khatri, et al.
Chemosphere, 2018
Sidra Iftekhar, Mehmet Emin Küçük, Varsha Srivastava, et al.
Chemosphere, 2018
Georg Johansson, Georg Lundgren, Lars Gunnar Sillén, et al.
Acta Chemica Scandinavica, 1960
L. Irbe, R.E. Beddoe, D. Heinz
Cement and Concrete Research, 2019
N.Y. Mostafa, A.A. Shaltout, H. Omar, et al.
Journal of Alloys and Compounds, 2009
Mitsunori Yada, Masato Machida, Tsuyoshi Kijima
Chem. Commun., 1996
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
When used as a deodorant, the volume of sweat produced is reduced by narrowing sweat ducts.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
Volume of distribution
[L2152]
Elimination
2%
[L2155]
…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
It is a chemical agent used in water purification, the pH regulation of garden soil, and other commercial or industrial applications. Medically, it is primarily used as a coagulating agent in minor cuts and abrasions as well as deodorant [L2144].
Aluminum (Al) is ubiquitous and represents the third most common element in the Earth’s crust. It most commonly exists in a combined state with various other elements. Al is found in materials used in the pharmaceutical industry, and in manufactured foodstuffs, cosmetics, and tap water. By overcoming the body barriers, Al may infiltrate into the blood and lead to toxic effects in liver, bone and the central nervous system [L2145].
[L2149]
It is often purchased over the counter and is available in solid stick or powder form for minor cuts and abrasions after shaving .
[L2157], [L2164]
Aluminum sulfate is also used as an adjuvant in vaccines .
[L2158]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 29 of 29 interactions
Acute: >9000 mg/kg in the mouse MSDS. >9000 mg/kg in the rat MSDS.
Acute Toxicity
There is little indication that aluminum is acutely toxic by oral exposure despite it is widely found in foods, drinking water, and many antacid preparations .
[L2149]
In 1988, a population of about 20 000 citizens of Camelford, England, was exposed to increased levels of aluminum for 5 days. The aluminum was accidentally ingested by the population from a water supply facility using aluminum sulfate for water treatment .
[L2149]
Some adverse effects observed were nausea, vomiting, diarrhea, mouth ulcers, skin ulcers, skin rashes, and arthritis-type pain were observed. It was concluded in one study that the adverse effects of aluminum sulfate were primarily mild and transient.
No long-lasting effects on health could be attributed to the exposures from aluminum in the drinking water during this period .
[L2149]
Chronic Toxicity
In humans, excess exposure to aluminum via dialysis water (aluminum sulfate) is a known etiological factor in several pathological conditions in patients treated with hemodialysis. Clinical symptoms and signs of aluminum toxicity include hypercalcemia, anemia, vitamin D refractory osteodystrophy, and a dialysis encephalopathy. Bone pain, pathological fractures, and proximal myopathy may occur.
Aluminum has also been suggested as an etiology of several neurodegenerative diseases such as Alzheimer senile and pre-senile dementia, as well amyotrophic sclerosis. Despite this, the most recent investigations have failed to confirm this hypothesis. A study in man has verified a number of possible deleterious interactions of aluminum salts with phosphorous metabolism, especially in long-term ingestion of aluminum-containing antacids .
[L2152]
It has been suggested that aluminum exposure is a risk factor for the development or acceleration of onset of Alzheimer disease (AD) in humans.
The world health organization has completed a meta-analysis of 20 epidemiological studies done to test the hypothesis that aluminum in drinking-water is a risk factor for Alzheimer disease. Six studies on populations in Norway were considered of sufficiently high quality to meet the general criteria for exposure and outcome assessment and the adjustment for at least some confounding variables .
[L2149]
Of six studies that examined the relationship between aluminum in drinking- water and dementia, three found a positive relationship, but three did not. However, each of the studies had significant deficiencies in the study design (e.g. ecological exposure assessment; failure to consider aluminum exposure from all sources and to control for important confounders, such as education, socioeconomic status, and family history; the use of surrogate outcome measures for AD; and selection bias) .
[L2149]
In general, the relative risks determined were less than 2, with large confidence intervals, when the total aluminum concentration in drinking-water was 0.1 mg/L or higher. Due to the pathogenesis of AD and knowledge obtained from studies, it was concluded that the present epidemiological evidence does not support a causal association between AD and aluminum in drinking-water .
[L2149]
In addition to the epidemiological studies that examined the relationship between AD and aluminum in drinking-water, two studies studied cognitive dysfunction in elderly populations in relation to the levels of aluminum in drinking water.
The results proved conflicting. A study of 800 male subjects, age 80-89, drinking water containing aluminum concentrations up to 98 μg/L found no relationship. The second study used “any evidence of mental impairment” as an outcome measure and found a relative risk of 1.72 at aluminum drinking-water concentrations above 85 μg/L in 250 males.
Such data are insufficient to show that aluminum is a cause of cognitive impairment in the elderly .
[L2149]
Note on possible risk of breast cancer
Widespread concern has been raised regarding the exposure to aluminum in deodorant/antiperspirant products, with inconclusive results .
[L2165], [L2167], [L2168], [L2169]
Results from a more recent case-control study suggest an association between underarm cosmetic use and aluminum concentration in breast tissue and breast cancer. The observed association of underarm cosmetic use with breast cancer was, however, limited to women who report using the products multiple times a day before age of 30 .
[A32464]
By inhibiting or deactivating odor-producing bacteria, there is little to none metabolism of sweat components thus decreasing the occurrence of body odor [L2160].
Recent studies suggest that the active binding of alum to the membranes of dendritic cells (DCs) result in alteration of lipid membranes structures as a key process in alum's adjuvant effect in vaccines. As new adjuvants are being developed, alum may remain as an ingredient of adjuvant combinations, or it may eventually be supplemented by other agents that more effectively provide depot and local inflammatory responses to accentuate host immune responses [L2158].
Used as a post-shaving treatment, it can eliminate bleeding from superficial wounds [L2157], [L2164].
It has also shown in vitro anti-microbial activity [L2160].
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L2149]
These facts should be taken into consideration during tissue dosimetry and response assessment to aluminum sulfate. It can be concluded that the use of currently available animal studies to develop a guideline value is inappropriate at this time due to the above specific toxicokinetic/dynamic factors that may affect results .
[L2149]
[L2156]
[L2152]
[L2155]
About 2% is excreted in bile .
[L2157]
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72